EGFR and non-small cell lung carcinoma: Similar circumvention of TKI resistance by Pt-Erlotinib and Pt-Vandetanib hybrids in NSCLC cell line (H1975) harboring the most prevalent resistance-causing secondary mutation (EGFR T790M) were also observed, but to a lesser extent (Table 1).